Does Lumateperone (Caplyta) work?

Read Off Label rates the evidence for Lumateperone (Caplyta) as Strong and the benefit magnitude as med-high, producing an overall grade of B (6.6/10). Intra-Cellular Therapies/J&J.

Is Lumateperone (Caplyta) safe?

Lumateperone (Caplyta) has a med risk profile in published human data. Legal status: Rx (FDA-approved: schizophrenia, bipolar depression, MDD adjunct). This is not medical advice — see the disclaimer.

Rankings / Mood, Anxiety & Stress

Lumateperone (Caplyta)

Mood, Anxiety & Stress · Atypical antipsychotic

Tier B

Reviewed by Read Off Label · Last reviewed Jun 7, 2026 · How we grade

atypical-antipsychoticdopamineserotoninmddprescription

6.6 / 10

Tier B

Ev 8 Bn 6.5 Sf 5

Bottom line

Read Off Label grades Lumateperone (Caplyta) as B (6.6/10) based on strong evidence, med-high benefit magnitude, and a med-risk safety profile.

Intra-Cellular Therapies/J&J.

Typical use: Oral 42 mg once daily — Rx.

What this is

Intra-Cellular Therapies/J&J. FDA-approved Nov 2025 as adjunctive therapy for major depressive disorder (4th indication, after schizophrenia and bipolar I/II depression): two Phase 3 trials (n=485; n=480) showed MADRS improvements of 4.9 and 4.5 points vs placebo; weight/metabolic effects similar to placebo. Industry-sponsored.

Mechanism

Atypical antipsychotic with serotonin (5-HT2A antagonist), dopamine (presynaptic partial agonist / postsynaptic antagonist) and glutamatergic activity, and a comparatively clean metabolic profile.

Dose & route

Oral 42 mg once daily

Citations

https://www.jnj.com/media-center/press-releases/fda-approval-of-caplyta-lumateperone-has-the-potential-to-reset-treatment-expectations-offering-hope-for-remission-in-adults-with-major-depressive-disorder

Links go to the source. If a link is dead or you want something re-checked, let me know.

Common questions

Does Lumateperone (Caplyta) work?: Read Off Label rates the evidence for Lumateperone (Caplyta) as Strong and the benefit magnitude as med-high, producing an overall grade of B (6.6/10). Intra-Cellular Therapies/J&J.
Is Lumateperone (Caplyta) safe?: Lumateperone (Caplyta) has a med risk profile in published human data. Legal status: Rx (FDA-approved: schizophrenia, bipolar depression, MDD adjunct). This is not medical advice — see the disclaimer.
What is the typical dose for Lumateperone (Caplyta)?: Oral 42 mg once daily
How does Lumateperone (Caplyta) work?: Atypical antipsychotic with serotonin (5-HT2A antagonist), dopamine (presynaptic partial agonist / postsynaptic antagonist) and glutamatergic activity, and a comparatively clean metabolic profile.

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.